The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.
Pfizer Inc. has a rare 3-year tariff exemption and margin defense amid global price parity risks. Click here to read an ...
Zacks Investment Research on MSN
Pfizer (PFE) outperforms broader market: What you need to know
In the latest trading session, Pfizer (PFE) closed at $25.90, marking a +1.49% move from the previous day. The stock's change ...
In the latest close session, Pfizer (PFE) was up +1.63% at $25.56. This move outpaced the S&P 500's daily loss of 0.53%. On ...
One of these suggested stocks features a dividend yield topping 10%.
Shares of Pfizer Inc. PFE rallied 1.71% to $25.58 Wednesday, on what proved to be an all-around poor trading session for the ...
Novavax shares are up on Monday following a licensing agreement with Pfizer for the use of its Matrix-M adjuvant.
Pfizer PFE stock has declined almost 5% in a month, losing $7.3 billion in market capitalization. Shares dipped recently ...
Pfizer's been focusing on a hot area of healthcare recently: GLP-1 drugs.
Novavax Inc. (NASDAQ:NVAX) shares are up 3.3% to trade at $8.27 at last glance, after the vaccine company singed a licensing ...
Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results